Beam Therapeutics Inc.

NasdaqGS:BEAM 株式レポート

時価総額:US$1.9b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Beam Therapeutics 過去の業績

過去 基準チェック /06

Beam Therapeuticsの収益は年間平均-14.1%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間15.5% 80.6%割合で 増加しています。

主要情報

-14.1%

収益成長率

45.6%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率80.6%
株主資本利益率-14.7%
ネット・マージン-37.3%
前回の決算情報31 Mar 2024

最近の業績更新

Recent updates

We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

May 13
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn

Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects

Apr 24

Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S

Apr 07
Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S

Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 01
Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade

Feb 29
Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade

Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now

Feb 08

This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year

Nov 01
This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year

We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely

Jul 23
We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely

Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation

Apr 08
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation

Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts

Nov 08
Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts

Beam Therapeutics: Now Is Not The Right Time To Own

Sep 15

Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M

Aug 09

Beam drops 19% as FDA issues clinical hold on blood cancer candidate

Aug 01

Revisiting Beam Therapeutics Among Collaborative Catalysts

Jul 10

Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts

May 10
Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts

Beam Therapeutics Worth Watching Because Of Pfizer Interest?

Apr 21

Beam Therapeutics: Getting More And More Interesting

Apr 10

Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Mar 03
Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 02
Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates

Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy

Jan 19

Beam Therapeutics: An Early Company In A Promising Field

Dec 27

Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity

Dec 20

Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio

Oct 01

Beam Therapeutics: If You Buy Into The Technology, Buy Into The Stock

Aug 25

収支内訳

Beam Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGS:BEAM 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Mar 24361-1351200
31 Dec 23378-1331170
30 Sep 2382-314960
30 Jun 2380-327930
31 Mar 2377-31692-54
31 Dec 2261-289880
30 Sep 2292-315830
30 Jun 2277-234770
31 Mar 2260-2386654
31 Dec 2152-371570
30 Sep 211-401480
30 Jun 210-408400
31 Mar 210-366330
31 Dec 200-196300
30 Sep 200-132270
30 Jun 200-119250
31 Mar 200-106230
31 Dec 190-91210
30 Sep 190-86180
30 Jun 190-134150
31 Mar 190-124130
31 Dec 180-117120

質の高い収益: BEAMは現在利益が出ていません。

利益率の向上: BEAMは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: BEAMは利益が出ておらず、過去 5 年間で損失は年間14.1%の割合で増加しています。

成長の加速: BEAMの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: BEAMは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。


株主資本利益率

高いROE: BEAMは現在利益が出ていないため、自己資本利益率 ( -14.75% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘